Three doses of the COVID-19 vaccine developed by Chinese company Sinovac Biotech fail to fully protect against the Omicron coronavirus variant, according to the latest study conducted in Hong Kong and published on Thursday.
However, people who have been inoculated with two Sinovac doses following Pfizer's booster shot have significantly more protective antibodies versus Omicron, as well as those who received two Pfizer doses.
Sinovac's research estimated the protection against Omicron at 94% following three vaccine doses.
